MetaCap

Lycia Therapeutics (LYCA) vs Maze Therapeutics (MAZE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.72 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LYCA+10.23%MAZE+1.16%
+20%+1%-18%
Oct 23, 20261 yearNov 20, 2026
LYCA+10.23%MAZE+1.16%
+12%-1%-13%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LYCA versus MAZE key metrics
MetricLYCAMAZE
Share price$33.07$31.37
Market cap$1.72B$1.72B
1-day change+4.09%-3.27%
YTD return—-24.28%
1-year return—-13.49%
EPS (TTM)$-1.04$-2.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-131.12M
52-week high$36.49$53.65
52-week low$22.19$21.95
Distance from 52-week high-9.37%-41.53%
Analyst consensus—strong_buy
Avg. price target upside—+99.11%
Average volume432.72K737.14K
Shares outstanding52.09M54.68M
Employees31141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

About Maze Therapeutics

MAZE stock →

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

LYCA vs MAZE FAQ

Which is bigger, Lycia Therapeutics or Maze Therapeutics?

Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.72B for Maze Therapeutics (MAZE).

Are Lycia Therapeutics and Maze Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons